IMMUNIC, INC.
About
Immunic, Inc. is a late-stage clinical biotechnology company focused on developing novel oral therapies for chronic inflammatory, autoimmune, neurologic, and gastrointestinal diseases. The company's primary focus is on its lead drug candidate, vidofludimus calcium, which is in Phase 3 trials for the treatment of multiple sclerosis. Immunic aims to address unmet needs by targeting mechanisms like Nurr1 activation and DHODH inhibition to offer neuroprotective and anti-inflammatory benefits.
Company Values
The company's lead candidate, vidofludimus calcium, is a first-in-class Nurr1 activator with a multi-mechanism profile, offering neuroprotective, anti-inflammatory, and antiviral effects. This dual-action approach is designed to address neurodegeneration in multiple sclerosis, a key aspect not fully covered by many existing inflammation-focused therapies.